Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells

Neoplasia

Volumn 9, Issue 4, 2007, Pages 349-357

  Millimaggi, Danilo ^a   Mari, Marianna ^a   D'Ascenzo, Sandra ^a   Carosa, Eleonora ^a   Jannini, Emmanuele Angelo ^a   Zucker, Stanley ^b   Carta, Gaspare ^c   Pavan, Antonio ^a,d   Dolo, Vincenza ^a,c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b STONY BROOK UNIVERSITY   (United States)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Angiogenesis; CD147; Matrix metalloproteinases; Ovarian cancer; Shed membrane microvesicles

Indexed keywords

CD147 ANTIGEN; COMPLEMENTARY DNA; MATRIX METALLOPROTEINASE; SMALL INTERFERING RNA;

ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA TRANSFECTION; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MEMBRANE VESICLE; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN; WESTERN BLOTTING;

EID: 34247197062     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07133     Document Type: Article

References (43)

1. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, and Nabeshima K (1995). The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55, 434-439.
2. Toole BP (2003). Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol 54, 371-389.
3. Davidson B, Goldberg I, Berner A, Kristensen GB, and Reich R (2003). EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 20, 161-169.
4. Tang Y, Kesavan P, Nakada MT, and Yan L (2004). Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2, 73-80.
5. Sun J and Hemler ME (2001). Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 61, 2276-2281.
6. Guo H, Zucker S, Gordon MK, Toole BP, and Biswas C (1997). Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem 272, 24-27.
7. Sidhu SS, Mengistab AT, Tauscher AN, LaVail J, and Basbaum C (2004). The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene 23, 956-963.
8. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, Branski P, Ratajczak MZ, and Zembala M (2006). Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 55, 808-818.
9. Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole BP, Zucker S, and Birembaut P (2002). EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 19, 697-702.
10. Stetler-Stevenson WG, Aznavoorian S, and Liotta LA (1993). Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9, 541-573.
11. Zucker S, Hymowitz M, Rollo EE, Mann R, Conner CE, Cao J, Foda HD, Tompkins DC, and Toole BP (2001). Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 158, 1921-1928.
12. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski P, and Yan L (2005). Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65, 3193-3199.
13. Reiland J, Kempf D, Roy M, Denkins Y, and Marchetti D (2006). FGF2 binding, signaling and angiogenesis are modulated by heparanase in metastatic melanoma cancer. Neoplasia 8, 596-606.
14. Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M, Boudreau N, Werb Z, and Rosen SD (2005). SULF-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 7, 1001-1010.
15. Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S, Berger J, Ebel S, Janicke F, Sauter G, et al. (2004). Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 10, 3422-3428.
16. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, and Dolo V (2002). Shedding of the matrix metalloproteinases MMP-2, MMP-9 and MT1-MMP as membrane vesicles-associated components by endothelial cells. Am J Pathol 160, 673-680.
17. Hugel B, Martinez MC, Kunzelmann C, and Freyssinet JM (2005). Membrane microparticles: two sides of the coin. Physiology (Bethesda) 20, 22-27.
18. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, and Sixma JJ (1999). Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 94, 3791-3799.
19. Dolo V, Ginestra A, Ghersi G, Nagase H, and Vittorelli ML (1994). Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. J Submicrosc Cytol Pathol 26, 173-180.
20. Stoorvogel W, Kleijmeer MJ, Geuze HJ, and Raposo G (2002). The biogenesis and functions of exosomes. Traffic 3, 321-330.
21. Ginestra A, Miceli D, Dolo V, Romano FM, and Vittorelli ML (1999). Membrane vesicles in ovarian cancer fluids: a new potential marker. Anticancer Res 19, 3439-3445.
22. Dolo V, Adobati E, Canevari S, Picone MA, and Vittorelli ML (1995). Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Clin Exp Metastasis 13, 277-286.
23. Dolo V, Ginestra A, Cassara D, Violini S, Lucania G, Torrisi MR, Nagase H, Canevari S, Pavan A, and Vittorelli ML (1998). Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res 58, 4468-4474.
24. Dolo V, D'Ascenzo S, Violini S, Pompucci L, Festuccia C, Ginestra A, Vittorelli ML, Canevari S, and Pavan A (1999). Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 17, 131-140.
25. Albanese J, Meterissian S, Kontogiannea M, Dubreuil C, Hand A, Sorba S, and Dainiak N (1998). Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles. Blood 91, 3862-3874.
26. Zitvogel L, Fernandez N, Lozier A, Wolfers J, Regnault A, Raposo G, and Amigorena S (1999). Dendritic cells or their exosomes are effective biotherapies of cancer. Eur J Cancer 35 (Suppl 3), S36-S38.
27. Ginestra A, Monea S, Seghezzi G, Dolo V, Nagase H, Mignatti P, and Vittorelli ML (1997). Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem 272, 17216-17222.
28. Angelucci A, D'Ascenzo S, Festuccia C, Gravina GL, Bologna M, Dolo V, and Pavan A (2000). Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin Exp Metastasis 18, 163-170.
29. Poste G and Nicolson GL (1980). Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. Proc Natl Acad Sci USA 77, 399-403.
30. Taverna S, Ghersi G, Ginestra A, Rigogliuso S, Pecorella S, Alaimo G, Saladino F, Dolo V, Dell'Era P, Pavan A, et al. (2003). Shedding of membrane vesicles mediates fibroblast growth factor-2 release from cells. J Biol Chem 278, 51911-51919.
31. Kim CW, Lee HM, Lee TH, Kang C, Kleinman HK, and Gho YS (2002). Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Res 62, 6312-6317.
32. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, and Ratajczak MZ (2005). Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 113, 752-760.
33. Dolo V, Ginestra A, Violini S, Miotti S, Festuccia C, Miceli D, Migliavacca M, Rinaudo C, Romano FM, Brisdelli F, et al. (1997). Ultrastructural and phenotypic characterization of CABA I, a new human ovarian cancer cell line. Oncol Res 9, 129-138.
34. Taraboletti G, Roberts D, Liotta LA, and Giavazzi R (1990). Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 111, 765-772.
35. Bordador LC, Li X, Toole B, Chen B, Regezi J, Zardi L, Hu Y, and Ramos DM (2000). Expression of emmprin by oral squamous cell carcinoma. Int J Cancer 85, 347-352.
36. Kanekura T, Chen X, and Kanzaki T (2002). Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 99, 520-528.
37. Millimaggi D, Festuccia C, Angelucci A, D'Ascenzo S, Rucci N, Flati S, Bologna M, Teti A, Pavan A, and Dolo V (2006). Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells. Int J Oncol 28, 909-914.
38. Reichardt W, Hu-Lowe D, Torres D, Weissleder R, and Bogdanov A Jr (2005). Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma. Neoplasia 7, 847-853.
39. Said NA, Najwer I, Socha MJ, Fulton DJ, Mok S, and Motamed K (2007). SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia 9, 23-35.
40. Zechmann CM, Woenne EC, Brix G, Radzwill N, Ilg M, Bachert P, Peschke P, Kirsch S, Kauczor HU, Delorme S, et al. (2007). Impact of stroma on growth, microcirculation and metabolism of experimental prostate tumors. Neoplasia 9, 57-67.
41. Taylor DD and Black PH (1986). Shedding of plasma membrane fragments. In Developmental Biology. Steinberg, M (Ed.). Plenum Press, New York, pp. 33-57.
42. Taraboletti G, D'Ascenzo S, Giusti I, Marchetti D, Borsotti P, Millimaggi D, Giavazzi R, Pavan A, and Dolo V (2006). Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia 8, 96-103.
43. Schiffelers RM, Metselaar JM, Fens MH, Janssen AP, Molema G, and Storm G (2005). Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia 7, 118-127.